Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP...
-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 1:00pm
Hemostemix dissolves all pending lawsuits with Aspire health
The long awaited moment for hemostemix has finally come. The company just got done with all the pending legal proceedings regarding the un-authorized possession of ACP-01’s clinical trial data has
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 29, 2022 12:38pm
Hemostemix hires new financial advisor to the family
Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has joined hemostemix as a special
...more
Discover Options Trading Strategies to Minimize your Tax Burden
posted Dec 01, 2024 9:00am by
Bank of Montreal
-
|
Options trading doesn’t come without tax implications, but there are ways investors can still optimize their after-tax returns with just a little bit of understanding. Approaches for investors to keep in mind are holding periods, wash-sales rule, tax advantaged accounts, and qualified cover calls. BMO’s enhanced InvestorLine platform. Industry-leading tools and capabilities specifically designed to empower options traders. ...read more
(3)
•••
tradeviewww
X
View Profile
View Bullboard History
Post by
tradeviewww
on Jun 28, 2022 3:25pm
$HMTXF about to issue the global field use license of NCP-01
Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous stem cell technology to treat central and peripheral nervous system diseases. Such as Neuropathic pain
...more
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 3:25pm
$HEM announcement related to the Stock Options Grant
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common
...more
(7)
•••
TRADERCONNECTS
X
View Profile
View Bullboard History
Post by
TRADERCONNECTS
on Jun 28, 2022 2:50pm
$HMTXF a praiseworthy stock multiplying in heavily
$HMTXF has been on quite an impressive venture, the stock is seen to have much potential by the investors and is a worthy investment, shares are trading at $0.1960 with a 0.20% jump in value.
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 1:31pm
$HEM Market Insight
Hemostemix is a clinical-stage biotechnology company trading in TSX-V with ticker symbol $HEM is currently sitting at $0.255 with volume of $8.62K+.
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 1:30pm
Hemostemix Inc. Market Graph
Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.255-$0.285. In the last 52 weeks it is $0.13-$0.42.
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 28, 2022 1:21pm
$HEM Stock Analysis and Evaluation
Hemostemix Inc. is an emerging biotechnology company listed on TSX-V with the ticker symbol $HEM traded today at price of $0.255 per share.
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 28, 2022 1:02pm
$HEM announced amalgamation of an entirely owned subsidiary
The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 28, 2022 10:13am
$HEM grants worldwide field license to PreCerv Inc.
Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central
...more
(9)
•••
maikaljarry
X
View Profile
View Bullboard History
Post by
maikaljarry
on Jun 28, 2022 9:23am
$HEM market cap shoot up to $17 Million
$HEM have developed and established a firm market cap which has been on the rise steadily since the listing of the stock on TSX-V, currently the cap valuation is $17.404Million.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 28, 2022 8:42am
Data audit efficiently executed, results came out to be auth
Hemostemix have been handed back its intellectual property consisting of all the clinical trial data of ACP-01 which was long unlawfully held by Accudata and Aspire Health Science, the data audit post
...more
(1)
•••
Pabloparker
X
View Profile
View Bullboard History
Post by
Pabloparker
on Jun 28, 2022 7:47am
Hemostemix Inc. (TSXV: HEM)(OTC: HMTXF) The Numero Uno Stock
www.marketwatch.com/.../hemostemix-inc-tsxv-hem-otc-hmtxf-the-numero-uno-stock-investment-in-the-game-2022-06-28
(147)
•••
RamboOO7
X
View Profile
View Bullboard History
Post by
RamboOO7
on Jun 28, 2022 5:44am
The big green blob on graph. Buying by insiders !!
https://m.canadianinsider.com/node/7?menu_tickersearch=THC+%7C+THC+Biomed+Intl
(147)
•••
RamboOO7
X
View Profile
View Bullboard History
Post by
RamboOO7
on Jun 28, 2022 5:41am
I am glad i bought and sold made profit. Reinvested in THC
Financials due in a couple of days. I think their biscuits are selling like hot cakes . A lot of buying buy the CEO and CFO lately. Looks like a big green blob of insider buying on the graph. DYODD
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >